Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-20T12:01:17.488Z Has data issue: false hasContentIssue false
  • English
  • Français

Regional Metal Concentrations in Parkinson's Disease, Other Chronic Neurological Diseases, and Control Brains

Published online by Cambridge University Press:  18 September 2015

Ryan J. Uitti ,
A.H. Rajput ,
B. Rozdilsky ,
M. Bickis ,
T. Wollin  and
W.K. Yuen
Ryan J. Uitti
Affiliation:
Department of Clinical Neurological Sciences, Saskatoon
A.H. Rajput*
Affiliation:
Department of Clinical Neurological Sciences, Saskatoon
B. Rozdilsky
Affiliation:
Department of Pathology, Saskatoon
M. Bickis
Affiliation:
Department of Mathematics and Statistics, Saskatoon
T. Wollin
Affiliation:
Department of Clinical Neurological Sciences, Saskatoon
W.K. Yuen
Affiliation:
University of Saskatchewan, and the Saskatchewan Research Council, Saskatoon
*
Dept. of Clinical Neurological Sciences, University Hospital, Saskatoon, Saskatchewan, Canada S7N 0X0
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Metal deficiency or toxicity states have been recognized as a cause of several neurological disorders and are suspected in others. We analyzed four brain regions (frontal cortex, caudate nucleus, substantia nigra, and cerebellum) in 36 human brains for concentrations of 24 metals (Ag, Al, As, B, Be, Ca, Cd, Co, Cr, Cu, Fe, K, Pb, Mg, Mn, Mo, Na, Ni, P, Se, Ti, V, W, Zn). Regional metal concentrations, measured using atomic absorption and atomic emission spectroscopy, were compared between 9 Parkinson's disease (PD) brains, 15 brains from patients with other chronic neurological diseases, and 12 control brains. No significant metal concentration differences were noted between brains from PD and other chronic neurologic disease. However, parkinsonian brains (PD and parkinsonism secondary to neurofibrillary tangle disease) showed lower concentrations of magnesium in the caudate nucleus and copper in the substantia nigra than control brains. These findings may represent an etiologically important clue to parkinsonism.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 16 , Issue 3 , August 1989 , pp. 310 - 314
Copyright
Copyright © Canadian Neurological Sciences Federation 1989

References

REFERENCES

1.Calne, DB, Langston, JW. Aetiology of Parkinson’s disease. Lancet 1983; 2: 1457–1459.CrossRefGoogle ScholarPubMed
2.Rajput, AH, Uitti, RJ, Stern, W, et al. Geology, drinking water chem-istry, pesticides and herbicides and the etiology of Parkinson’s disease. Can J Neurol Sci 1987; 14: 414–418.CrossRefGoogle Scholar
3.Davis, GC, Williams, AC, Markey, SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res 1979; 1: 249–254.CrossRefGoogle ScholarPubMed
4.Langston, JW, Ballard, P, Tetrud, JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–980.CrossRefGoogle ScholarPubMed
5.Dreosti, IE, Smith, RM. Neurobiology of the trace elements. Clifton, New Jersey: Humana Press 1983; Vols 1, 2.Google Scholar
6.Danks, DM. Hereditary disorders of copper metabolism in Wilson’s disease and Menke’s disease. In: Stanbury, JB, Wyngaarden, JB, Fredrickson, DS, Goldstein, JL, Brown, MS, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill 1983; 1251–1268.Google Scholar
7.Weiss, B. Behavioral toxicology of heavy metals. In: Dreosti, IE, Smith, RM, eds. Neurobiology of the Trace Elements. Clifton, New Jersey: Humana Press 1983; 2: 1–50.Google Scholar
8.Feldman, RG, Hayes, MK, Younes, R, et al. Lead neuropathy in adults and children. Arch Neurol 1977; 34: 481–488.CrossRefGoogle ScholarPubMed
9.Cotzias, GC, Papavasiliou, PS, Ginos, J, et al. Metabolic modifica-tion of Parkinson’s disease and of chronic manganese poisoning. Ann Rev Med 1971; 22: 305–326.CrossRefGoogle Scholar
10.Ferray, HB, Bertolucci, PHF, Pereira, JS, et al. Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication. Neurology 1988; 38: 550–553.CrossRefGoogle Scholar
11.Perl, DP, Gajdusek, DC, Garruto, RM, et al. Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and parkinsonism-dementiaofGuam. Science 1982; 217: 1053–1055.CrossRefGoogle Scholar
12.Asenjo, A. Cytosiderosis and iron deposits in ventrolateral nucleus of the thalamus in Parkinson’s disease. Clinical and experimental study. Johns Hopkins Med J 1968; 122: 284–294.Google ScholarPubMed
13.Rajan, KS, Manian, AA, Davis, JM, et al. Metal chelates of 1-dopa for improved replenishment of dopaminergic pools. Brain Res 1976; 107: 317–33.CrossRefGoogle Scholar
14.Hoogenraad, TU, Van Den Hamer, CJA, Van Hattum, J. Effective treatment of Wilson’s disease with oral zinc sulphate: two case reports. Br Med J 1984; 289: 273–276.CrossRefGoogle ScholarPubMed
15.Alexander, PE, van Kammen, DP, Bunney, WE Jr. Serum calcium and magnesium levels in schizophrenia. Arch Gen Psychiatry 1979; 36: 1372–1377.CrossRefGoogle ScholarPubMed
16.Uitti, RJ, Rajput, AH, Rozdilsky, B, et al. Regional distribution of metals in human brain. Clin Invest Med 1987; 10: 10–13.Google ScholarPubMed
17.Gnanadesikan, R. Methods of statistical data analysis of multivari-ate observations. New York: Wiley 1977.Google Scholar
18.Miller, RG Jr. Simultaneous statistical inference. New York: Springer-Verlag 1981.CrossRefGoogle Scholar
19.Rao, CR. Linear statistical inference and its applications. NewYork: Wiley 1973.CrossRefGoogle Scholar
20.Rajput, AH, Uitti, RJ, Rozdilsky, B, et al. Distribution of metals in Parkinson’s disease and control brains. Neurology 1985; 35 (Suppl 1): 224.Google Scholar
21.Poryali, A. Hypomagnesia and diseases of extrapyramidal system. Thesis 1960.Google Scholar
22.Barbeau, A, Jasmin, G, Duchastel, Y. Biochemistry of Parkinson’s disease. Neurology 1963; 13: 56–58.CrossRefGoogle ScholarPubMed
23.Schwab, RS, Poryali, A, Ames, A III. Normal serum magnesium lev-els in Parkinson’s disease. Neurology 1964; 14: 855–856.CrossRefGoogle Scholar
24.Barbeau, A, Rojo-ortega, JM, Brecht, HM, et al. Effect of a magne-sium-deficient diet on the striatal content of amines in the dog. Experientia 1972; 28: 289–291.CrossRefGoogle ScholarPubMed
25.Chitre, VS, Punekar, BD. Changes in serum copper and PPD oxi-dase in different diseases. Part II. Comparative studies in Wilson’s disease, schizophrenia and Parkinsonism. Indian J Med Res 1970; 58: 563–573.Google Scholar
26.Pall, HS, Blake, DR, Gutteridge, JM, et al. Raised cerebrospinal-fluid copper concentration in Parkinson’s disease. Lancet 1987; 2: 238–241.CrossRefGoogle ScholarPubMed
27.O’Dell, BL, Prohaska, JR. Biochemical aspects of copper deficiency in the nervous system. In: Dreosti, I.E., Smith, RM, eds. Neurobiology of the Trace Elements, Vol. 1. Clifton, New Jersey: Humana Press 1983; 41–81.CrossRefGoogle Scholar
28.Morgan, RF, O’Dell, BL. Effect of copper deficiency on the concen-trations of catecholamines and related enzyme activities in the rat brain. J Neurochem 1977; 28: 207–211.CrossRefGoogle Scholar
29.Weiner, WJ, Nausieda, PA, Klawans, HL. The effect of levodopa, lergotrile, and bromocriptine on brain iron, manganese, and copper. Neurology 1978; 28: 734–737.CrossRefGoogle ScholarPubMed
30.Drayer, BP, Olanow, CW, Burger, P. High field strength resonance imaging in patients with Parkinson’s disease. Neurology 1986; 36 (Suppl 1): 309.Google Scholar